Evaluation of the effectiveness of differentiated therapy of non-alcoholic fatty liver disease

Cover Page

Cite item

Full Text

Abstract

Aim. Study of the effectiveness of differentiated therapy of non-alcoholic fatty liver disease taking into account the clinical and pathogenetic features of its course.

Materials and methods. 168 patients with non-alcoholic fatty liver disease were examined, 108 of them were women and 60 men aged from 30 to 70 years. For treatment, depending on the characteristics of the course of the disease, 3 groups of patients were formed. The first group included patients (n=47) with liver steatosis with a high content of lipids in the blood and an increased atherogenic coefficient; they received therapy with ursodeoxycholic acid with atorvastatin. The second group consisted of patients (n=65) with liver steatosis with an increased level of glycemia, insulin and insulin resistance, they were prescribed therapy with ursodeoxycholic acid and metformin. Patients of the third group (n=56) with steatohepatitis with concomitant bacterial overgrowth received еssentiale forte H therapy with rioflora immuno. Clinical data, blood biochemical parameters, insulin and HOMA-IR levels, intestinal microbiota status, as well as regression of liver steatosis and steatohepatitis were evaluated in the dynamics of treatment.

Results. In the dynamics of treatment, there was a decrease in the clinical manifestations of the disease in all observed groups of patients, an improvement in lipid metabolism and indicators of the functional state of the liver, a decrease in excessive bacterial growth. On the basis of ultrasound, elastography and fibrotest, the reverse development of liver steatosis was found in 20% and steatohepatitis in 66.6% of patients.

Conclusion. The data obtained indicate the feasibility of differentiated treatment of patients with non-alcoholic fatty liver disease depending on the characteristics of its course and stage.

About the authors

Ya. M. Vakhrushev

Izhevsk State Medical Academy

Email: anna.lukashevich.89@mail.ru

д.м.н., проф., зав. каф. пропедевтики внутренних болезней с курсом сестринского дела

Russian Federation, Izhevsk

E. V. Suchkova

Izhevsk State Medical Academy

Email: anna.lukashevich.89@mail.ru

д.м.н., доц. каф. пропедевтики внутренних болезней с курсом сестринского дела

Russian Federation, Izhevsk

A. P. Lukashevich

Izhevsk State Medical Academy

Author for correspondence.
Email: anna.lukashevich.89@mail.ru

к.м.н., ассистент каф. пропедевтики внутренних болезней с курсом сестринского дела

Russian Federation, Izhevsk

References

  1. Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования Direg 2. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2015;25(6):31-41 [Ivashkin VT, Drapkina OM, Mayev IV, Trukhmanov AS, Blinov DV, Palgova LK, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2015;25(6):31-41 (In Russ.)].
  2. Подымова С.Д. Современный взгляд на патогенез и проблему лечения неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2016;(5):74-82 [Podymova SD. The modern view on pathogenesis and treatment of nonalcoholic fatty liver disease. Eksperimentalnaya i Klinicheskaya Gastroenterologiya. 2016;(5):74-82 (In Russ.)].
  3. Сучкова Е.В., Горбунов А.Ю., Вахрушев Я.М. К вопросу о способствующих факторах, механизмах развития и лечении жирового гепатоза. Медицинский альманах. 2012;20(1):73-5 [Suchkova EV, Gorbunov AYu, Vakhrushev YaM. About the issue of contributing factors, development mechanisms and treatment of fatty hepatosis. Medicinskij Almanah. 2012;20(1):73-5 (In Russ.)].
  4. Хохлачева Н.А., Сучкова Е.В., Вахрушев Я.М. Пути повышения эффективности диспансеризации больных ранней стадией желчнокаменной болезни. Экспериментальная и клиническая гастроэнтерология. 2013;(6):15-20 [Hohlacheva NA, Suchkova EV, Vahrushev YaM. Ways to improve efficiency of patients with early stage clinical examination of cholelithiasis. Eksperimentalnaya i Klinicheskaya Gastroenterologiya. 2013;(6):15-20 (In Russ.)].
  5. Сучкова Е.В. Функциональное состояние гепатобилиарной системы при жировом гепатозе у больных с сахарным диабетом. Экспериментальная и клиническая гастроэнтерология. 2009;(8):26-9 [Suchkova EV. Functional state of the hepatobiliary system in case of non-alcoholic fatty liver disease in patients with diabetes mellitus. Eksperimentalnaya i Klinicheskaya Gastroenterologiya. 2009;(8):26-9 (In Russ.)].
  6. Комова А.Т., Маевская М.В., Ивашкин В.Т. Принципы эффективной диагностики диффузных заболеваний печени на амбулаторном этапе. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2014;24(5):36-41 [Komova AT, Maevskaya MV, Ivashkin VT. Principles of effective diagnosis of diffuse liver diseases at the outpatient stage. Rossijskij Zhurnal Gastroenterologii, Gepatologii i Koloproktologii. 2014;24(5):36-41 (In Russ.)].
  7. Aijaz Ahmed MD, Ryan B, Perumpail MD, Stephen А, Harrison MD. Hige prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? Hepatology. 2016;63(1):20-2. doi: 10.1002/hep.28277
  8. Younossi ZM, Koening АВ, Abdelatif DA, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease. Meta-analytic assement of prevalence, incidence and outcomes. Hepatology. 2016;64(1):73-84. doi: org/10.1002/hep.28431
  9. Miura K, Ohnishi Н. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381
  10. Rolfe LD. Interactions among microorganisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis. 1984;6(1):73-9. doi: 10.1093/clinids/6.supplement_1.s73
  11. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fang SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-7. doi: 10.1002/hep.26319
  12. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2012;57:601-9. doi: 10.1002/hep.26093
  13. Волкова Н.И., Поркшеян М.И. Неалкогольная жировая болезнь печени: что мы знаем и что предстоит узнать. Терапевтический архив. 2017;89(2):91-8 [Volkova NI, Porksheyan MI. Nonalcoholic fatty liver disease: What do we know and what will we have to learn? Therapeutic Archive. 2017;89(2):91-8 (In Russ.)].
  14. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. Brit Med J. 2011;343:6891. doi: 10.1136/bmj.d6891
  15. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53(1):325-35. doi: 10.1002/hep.24013
  16. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. Position statement on NAFLD/NASH based on the EASL 2009 Special Conference. J Hepatol. 2010;53:372-84. doi: 10.1016/j.jhep.2010.04.008
  17. Tacuma Y, Nouso K. Nonalcoholic steatohepatitis associated hepatocellular carcinoma: our case series and literature review. Wld J Gastroenterol. 2010;16(12):1436-41. doi: 10.3748/wjg.v16.i12.1436
  18. Rutishauser J. The role of statins in clinical medicine – LDL-cholesterol lowering end beyond. Swiss Med Wkly. 2006;131:41-9. doi: 10.4414/smw.2011.13310
  19. Клебанова Е.М., Варийчук Ж.И. Роль метформина (глиформина) в лечении больных сахарным диабетом 2 типа. РМЖ. 2010;18(14):919-23 [Klebanova EM, Varijchuk ZhI. The role of metformin (glyformin) in the treatment of patients with diabetes mellitus. Russkij Medicinskij Zhurnal. 2010;18(14):919-23 (In Russ.)].
  20. Вахрушев Я.М., Сучкова Е.В. Урсодезоксихолевая кислота снижает риск желчного камнеобразования при жировом гепатозе. Врач-аспирант. 2011;4.5(47):727-31 [Vakhrushev YaM, Suchkova EV. Ursodeoxycholic acid reduces the risk of cholelithogenesis in fatty hepatosis. Vrach-aspirant. 2011;4.5(47):727-31 (In Russ.)].
  21. Xiang Z, Chen YP, Ma KF. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review BMC. Gastroenterology. 2013;13:140. doi: 10.1186/1471-230x-13-140
  22. Старостина Е.Г. К вопросу о сердечно-сосудистой эффективности и безопасности метформина. Атмосфера. Новости кардиологии. 2015;(3):38-46 [Starostina EG. On the question of cardiovascular efficacy and safety of metformin. Atmosfera. Novosti Kardiologii. 2015;(3):38-46 (In Russ.)].
  23. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22:873-83. doi: 10.1185/030079906x104696
  24. Korrenaga M, Kawaguchi K, Korrenaga K, Uchida K, Sakaida I. Insulin sensitizer anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance. Nippon Rinsho. 2006;64(6):1157-64.
  25. Viollet B, Guigas В, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Сellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond.). 2012;122:253-70. doi: 10.1042/cs20110386
  26. Ильченко Л.Ю., Осканова Р.С., Федоров И.Г. Эссенциальные фосфолипиды: от фармакологических свойств к терапевтическому эффекту. Терапия. 2015;2(2):56-63 [Ilchenko LYu, Oskanova RS, Fedorov IG. Essential phospholipids: from pharmacological properties to therapeutic effect. Terapiya. 2015;2(2):56-63 (In Russ.)].
  27. Зверков И.В., Минушкин О.Н. Сравнительная характеристика эффективности препаратов эссенциальных фосфолипидов и урсодезоксихолевой кислоты в терапии хронических заболеваний печени. Русский медицинский журнал. Медицинское обозрение. 2018;(7-1):33-6 [Zverkov IV, Minushkin ON. Comparative characteristics of the effectiveness of essential phospholipids and ursodeoxycholic acid in the treatment of chronic liver diseases. Russkij Medicinskij Zhurnal. Medicinskoe Obozrenie. 2018;(7-1):33-6 (In Russ.)].

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies